DOCTORS'
Medical Case Studies
DOCTORS'
Medical Case Studies
Velcade
Bortezomib
Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.
Velcade - List of case studies
- Multiple Myeloma (MM) and Cardiomyopathy
-
anti-MM induction type of treatment, including bortezomib (velcade), thalidomide and dexamethasone (the VTD combination x3), followed by ... status, amyloidosis. Medicines : bortezomib, velcade, thalidomide, dexamethasone, cyclophosphamide, melphalan, ... bortezomib, velcade, thalidomide, dexamethasone, cyclophosphamide, melphalan, ...
- Multiple myeloma with renal involvement, bone lesions and Neuropathy
-
combined treatment Melphalan-Thalidomide-Dexamethasone-Velcade according to the national GIMEMA protocol; thereafter the patient was ... cytoreduction treatment was changed with the inclusion of Velcade 1.3 mg/mq on days 1-5-8-12 for August; 25-28-1-4 for September; 9/29 ...
- Drugs
-
Valproic acid Vandetanib Vasodilators Velcade Venofen Verapamil Vertiserc Vestibular suppressant ...
- IgG Multiple Myeloma
-
in globulins, the IG – G and the light chains). Velcade with Dexacort was started with a good response. After 6 cycles of Velcade, the patient is currently on Thalidomide . Following is a summary ...